CA2709411A1 - Binding agents to the integrin alpha-11 subunit, and uses thereof - Google Patents

Binding agents to the integrin alpha-11 subunit, and uses thereof Download PDF

Info

Publication number
CA2709411A1
CA2709411A1 CA2709411A CA2709411A CA2709411A1 CA 2709411 A1 CA2709411 A1 CA 2709411A1 CA 2709411 A CA2709411 A CA 2709411A CA 2709411 A CA2709411 A CA 2709411A CA 2709411 A1 CA2709411 A1 CA 2709411A1
Authority
CA
Canada
Prior art keywords
antibody
antigen
binding fragment
fusion
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2709411A
Other languages
English (en)
French (fr)
Inventor
Evy Lundgren-Akerlund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cartela R&D AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0625144A external-priority patent/GB0625144D0/en
Priority claimed from GB0625165A external-priority patent/GB0625165D0/en
Application filed by Individual filed Critical Individual
Publication of CA2709411A1 publication Critical patent/CA2709411A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2709411A 2006-12-18 2007-12-18 Binding agents to the integrin alpha-11 subunit, and uses thereof Abandoned CA2709411A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US87538806P 2006-12-18 2006-12-18
US87538906P 2006-12-18 2006-12-18
US60/875,389 2006-12-18
GB0625144A GB0625144D0 (en) 2006-12-18 2006-12-18 Novel binding agents
GB0625165.6 2006-12-18
US60/875,388 2006-12-18
GB0625144.1 2006-12-18
GB0625165A GB0625165D0 (en) 2006-12-18 2006-12-18 Novel binding agents and uses thereof
PCT/GB2007/004886 WO2008075045A1 (en) 2006-12-18 2007-12-18 Binding agents to the integrin alpha-11 subunit, and uses thereof

Publications (1)

Publication Number Publication Date
CA2709411A1 true CA2709411A1 (en) 2008-06-26

Family

ID=42663774

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2709411A Abandoned CA2709411A1 (en) 2006-12-18 2007-12-18 Binding agents to the integrin alpha-11 subunit, and uses thereof

Country Status (6)

Country Link
US (1) US20110256061A1 (enExample)
EP (1) EP2101818A1 (enExample)
JP (1) JP2010514413A (enExample)
AU (1) AU2007335988A1 (enExample)
CA (1) CA2709411A1 (enExample)
WO (1) WO2008075045A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055231A1 (en) 1998-10-28 2003-03-20 Jian Ni 12 human secreted proteins
WO2015035235A1 (en) * 2013-09-06 2015-03-12 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Compositions and methods for increasing mesenchymal stromal cell migration to tumors
EP3517549A1 (en) * 2018-01-24 2019-07-31 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
EP3524625A1 (en) 2018-02-08 2019-08-14 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
JP7440718B2 (ja) * 2018-03-01 2024-02-29 恭之 横崎 抗インテグリンα１１モノクローナル抗体、およびその利用
JP2023508286A (ja) * 2019-12-20 2023-03-02 モメンタ ファーマシューティカルズ インコーポレイテッド インテグリンアルファ１１ベータ１に対する抗体
JPWO2023238845A1 (enExample) * 2022-06-07 2023-12-14
JP2025539271A (ja) * 2022-10-24 2025-12-04 フィブロコア セラピューティクス インコーポレイテッド インテグリンアルファ１１に結合する抗体、およびその用途
US20250332281A2 (en) 2023-12-15 2025-10-30 Capstan Therapeutics, Inc. Humanized anti-cd8 antibodies and uses thereof
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902056D0 (sv) * 1999-06-03 1999-06-03 Active Biotech Ab An integrin heterodimer and an alpha subunit thereof
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20060123495A1 (en) * 2002-04-12 2006-06-08 Donald Gullberg Knockout mice and their use
CA2593777C (en) * 2005-01-13 2014-12-02 Gene Techno Science Co., Ltd. Anti-.alpha.9 integrin antibody and the use thereof
WO2008075038A1 (en) * 2006-12-18 2008-06-26 Bioinvent International Ab Binding agents to the integrin alpha-11 subunit

Also Published As

Publication number Publication date
AU2007335988A1 (en) 2008-06-26
US20110256061A1 (en) 2011-10-20
WO2008075045A1 (en) 2008-06-26
JP2010514413A (ja) 2010-05-06
EP2101818A1 (en) 2009-09-23

Similar Documents

Publication Publication Date Title
US20240124596A1 (en) Antibody molecule for human gm-csf receptor alpha
CA2709411A1 (en) Binding agents to the integrin alpha-11 subunit, and uses thereof
KR20120108061A (ko) 아포지단백질 ｅ의 ｃ­말단 단편에 결합하는 항체
JP2015131800A (ja) オステオプロテゲリン結合タンパク質のアンタゴニスト性選択的結合因子
CA3168591A1 (en) Plasma kallikrein binding proteins
KR20100033523A (ko) Ｐａｒ－２에 결합하는 항원 결합 단백질
US7935793B2 (en) Treatment of inflammatory bowel diseases with anti-IP-10 antibodies
WO2008075038A1 (en) Binding agents to the integrin alpha-11 subunit
CN112243443B (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
CN114685666B (zh) 抗间皮素纳米抗体及其应用
EP1708961B1 (en) Anti-ip-10 antibodies
WO2023051618A1 (zh) Ctla-4结合分子及其应用
CN101528777B (zh) 抗胞外基质蛋白的rgd氨基酸序列的抗体及其制法与用途
AU2007231128B2 (en) Binding member for GM-CSF receptor
HK1166989B (en) Binding member for gm-csf receptor
HK1166988B (en) Binding member for gm-csf receptor

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20131218